TWiV 1142: Clinical update with Dr. Daniel Griffin

This Week in Virology

In his weekly clinical update, Dr. Griffin discusses global transmission of mpox, the different clades of the virus and associated pathogenesis, vaccination vs antiviral therapy against mpox and the US’s aid response for controlling the African outbreak before reviewing the recent statistics on SARS-CoV-2 infection, authorization and approval of updated COVID vaccines, the economic benefit of an annual COVID vaccine and if the first updated vaccines against XBB.1.5 were effective, where to find PEMGARDA, breakthrough infections when administering PEMGARDA, when to use convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, and how long COVID differs in children and adolescents.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• mpox epidemic caused by monkeypox clade I in affected African countries (European Centre for Disease Prevention and Control)
• mpox in Pakistan (Reuters)
• mpox imported into Pakistan (UNMC Global Center for Health Security)
• mpox domesticated in Taiwan (Focus Taiwan: CAN English News)
• clade IIb not Ib in Taiwan (bne Intellinews)
• WHO: mpox public health emergency of global care (NY Times)
• Vaccines didn’t turn back mpox…..people did (NY Times)
• Deadlier mpox version in Thailand (NY Times)
• Antiviral tecovirimat….not so much (NIH News)
• What about vaccines? (Bavarian Nordic)
• Invest or not to invest Barvaian Nordic pox vaccine manufacturer? (Yahoo! Finance)
• US to support Africa’s mpox response (CIDRAP)
• $35M to support mpox outbreak response in central and eastern Africa (USAID From the AMERICAN PEOPLE)
• COVID-19 deaths (CDC)
• COVID-19 national and regional trends (CDC)
• COVID-19 variant tracker (CDC)
• FDA approves and authorizes updated mRNA COVID-19 vaccines (FDA)
• Novavax still working on updated COVID-19 vaccine (novavax)
• COVID-19 variant update (CDC & IDSA)
• Economic benefit of annual COVID-19 vaccination (JID)
• Early COVID-19 XBB.1.5 vaccine effectiveness (Influenza and other respiratory viruses)
• Uptake of COVID-19 vaccines and associated hospitalization due to COVID-19 in pregnancy (Vaccine)
• Novavax heterologous booster demonstrates lower reactogenicity (JID)
• Where to get pemgarda (Pemgarda)
• EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
• Breakthrough from pemivibart/permgarda (bioRxiv)
• CDC Quarantine guidelines (CDC)
• Early phase of SARs-CoV-2 infection (COVID.gov)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Drug interaction checker (University of Liverpool)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What to do when sick with a respiratory virus (CDC)
• When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Long COVID differs in children and adolescents (JAMA Network)
• Letters read on TWiV 1142
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [e-mail]